Up a level |
Journal Article
Al-Batran, S-E., Hofheinz, R. D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, H-G., Pink, D., Siegler, G. M., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Bankstahl, U. S., Pauligk, C., Goetze, T. O. and Homann, N. (2020). Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. Ann. Oncol., 31. S. S901 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Perkhofer, L., Striefler, J. K., Sinn, M., Opitz, B., Goetze, T. O., Gallmeier, E., von Weikersthal, L. Fischer, Jacobasch, L., Waldschmidt, D., Niedermeier, M., Sohm, M., Sookthai, D., Berger, A., Beutel, A., Seufferlein, T. and Ettrich, T. J. (2021). Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group. Ann. Oncol., 32. S. S1282 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041